医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aryballe Technologies Appoints Top Consumer Industry Executive Jean-Christophe Simon as New Chairman of the Board to Help Drive Next Phase of Growth

2018年09月28日 PM11:00
このエントリーをはてなブックマークに追加


 

GRENOBLE, France

Aryballe Technologies (www.aryballe-technologies.com), the pioneer in digital olfaction, has appointed Dr Jean-Christophe Simon as its Chairman of the Board. He will bring to Aryballe his vision about transformation of food tech and cosmetic industries. Aryballe’s bio-inspired “digital nose” NeOseTM Pro, mimicking the human olfactory receptors that recognize smells, uses sensors to detect, measure and identify several hundreds of odors improving quality control, safety, and sensory evaluation important to multiple industries. Dr Simon will drive Aryballe’s industry expansion as the demand and use applications for this smart sensory technology continues to increase.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180928005201/en/

Aryballe Technologies appoints Jean-Christophe Simon as new Chairman of the Board (Photo: Jean-Chris ...

Aryballe Technologies appoints Jean-Christophe Simon as new Chairman of the Board (Photo: Jean-Christophe Simon)

With more than 25 years in R&D and innovation management, Dr Simon joins Aryballe with a dynamic and proven successful career in the innovation of consumer products for the food, home appliances and cosmetic industries.

“We’re delighted and honored to welcome Jean-Christophe as Aryballe’s Chairman of the Board,” said Sam Guilaumé, Aryballe CEO. “His global industry experience and international vision will have a profound impact on our advancement as a global technology leader in digital olfaction and help position the company for transformative growth.”

“Aryballe’s technology is groundbreaking. I am excited to have the opportunity to build on Aryballe’s success in the food and beverage, fragrance and cosmetic, and automotive industries, and to help expand the reach of Aryballe’s versatile technology,” said Jean-Christophe Simon. “Aryballe has created diverse applications to deliver outstanding industry outcomes, B2B as well as B2C. I look forward to working with this experienced and passionate team to contribute to Aryballe’s next developments as Chairman of the Board.”

Most recently, Dr Simon, since his appointment in 2010, served as the Chief Innovation Officer and Senior Vice-President of the Group Research at Groupe SEB. Dr Simon started his career in public research. He then joined the cosmetic company L’Oréal before moving to Japan and Germany to bring his experience to the Kao group. He has held the position of president and representative director of the Nikon and Essilor International Joint Research Center.

“Jean-Christophe is uniquely suited to serve as Chairman and will play a vital role in capitalizing Aryballe’s recent accomplishments. He has the proven track record and leadership experience to make great strides as we innovate for the future of digital olfaction bringing smell to the forefront of smart technology,” added Tristan Rousselle, Aryballe’s Deputy CEO.

About Aryballe

Aryballe, a startup based in Grenoble, France, develops and manufactures bio-inspired odor sensors enabling groundbreaking applications in the food, cosmetics and automotive industries. Founded in 2014, it released its first product, the digital nose NeOseTM Pro in early 2018. Fast, portable and sensitive to hundreds of odors, NeOseTM Pro is used for quality control in the cosmetic industry, new flavors development in the Food & Beverage industry, or materials quality monitoring in the automotive industry.

For further information visit: www.aryballe-technologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005201/en/

CONTACT

Media Contact:
Aryballe Technologies
Sam Guilaumé
sam@aryballe.com
contact@aryballe.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続